Syntocinon

# Syntocinon ## Overview - **Classification**: Oxytocic agent - **Mechanism**: Directly stimulates uterine smooth muscle, causing contractions. Also promotes milk ejection (let-down) via myoepithelial cell contraction. ## Primary Indications 1. **Induction of labor**: For medical indications when continuing pregnancy poses a risk. 2. **Augmentation of labor**: To improve uterine contractions in dysfunctional labor. 3. **Postpartum hemorrhage (PPH) prevention/treatment**: To prevent or control uterine atony and bleeding after placental delivery. 4. **Incomplete/Inevitable abortion**: As adjunct therapy to aid uterine evacuation. ## Adult Dosing ### Standard Dosing **Induction or Augmentation of Labor** - **Dose**: Initially **0.5-1 milliunit/minute** (mU/min). - **Frequency**: Increase gradually by **1-2 mU/min** every **30-60 minutes**. - **Route**: IV infusion, via an infusion pump. - **Maximum**: Typically **20 mU/min** (some cases up to 40 mU/min, but **20 mU/min** is a common maximum). - **Special Considerations**: Titrate to achieve a labor pattern similar to normal spontaneous labor (e.g., 3 contractions in 10 minutes, lasting 40-60 seconds). Continuous fetal heart rate and uterine activity monitoring required. **Prevention of Postpartum Hemorrhage** - **Dose**: **10 units** (U). - **Frequency**: Single dose immediately after delivery of the placenta. - **Route**: IM injection or **10-20 units** (U) diluted in **500-1000 mL** IV fluid, infused at **20-40 mU/min**. - **Duration**: Infusion maintained until risk of atony passes, typically for several hours. **Treatment of Postpartum Hemorrhage** - **Dose**: **10-40 units** (U) diluted in **500-1000 mL** IV fluid. - **Frequency**: Infused at a rate sufficient to control uterine atony, often **20-40 mU/min** initially. - **Route**: IV infusion. - **Maximum**: Total cumulative dose generally kept below **3 L** of oxytocin-containing fluid. - **Special Considerations**: Rapid administration can cause hypotension. **Incomplete/Inevitable Abortion** - **Dose**: **10 units** (U) in **500 mL** 0.9% NaCl or D5W. - **Frequency**: Infuse at **20-40 drops/min** (approx. 20-40 mU/min). - **Route**: IV infusion. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustments recommended; monitor for fluid overload and hyponatremia. - **Hepatic Impairment**: No specific dose adjustments recommended; monitor for fluid overload and hyponatremia. - **Elderly Patients**: Not indicated, as primary use is obstetric. ## Pediatric Dosing *Syntocinon is primarily an obstetric drug and is generally not indicated in pediatric patients for its approved uses.* ### Neonates (0-28 days) - **Dose**: **Not indicated**. - **Special Notes**: No established role for oxytocin in this age group for its approved indications. ### Infants (1-12 months) - **Dose**: **Not indicated**. - **Special Notes**: No established role for oxytocin in this age group for its approved indications. ### Children (1-12 years) - **Dose**: **Not indicated**. - **Special Notes**: No established role for oxytocin in this age group for its approved indications. ### Adolescents (13-18 years) - **Dose**: **Adult dosing applies** for obstetric indications if the patient is pregnant. - **Maximum**: **Adult dose limits apply**. - **Special Notes**: Use as per adult guidelines for labor induction/augmentation or PPH prevention/treatment. ## Safety Information ### Contraindications - **Absolute**: Significant cephalopelvic disproportion (CPD). - **Absolute**: Fetal distress (unless delivery is imminent). - **Absolute**: Unfavorable fetal presentation or position (e.g., transverse lie). - **Absolute**: Hypertonic uterine contractions or uterine hyperstimulation. - **Absolute**: Placenta previa, vasa previa, or umbilical cord prolapse. - **Absolute**: History of uterine rupture or major uterine surgery (e.g., classical C-section). - **Absolute**: Known hypersensitivity to oxytocin. - **Relative**: Multiparity (high parity) due to increased risk of uterine rupture. ### Common Adverse Effects - **Very Common (>10%)**: Uterine hypertonicity, uterine spasm. - **Common (1-10%)**: Nausea, vomiting. - **Serious but Rare**: Uterine rupture, fetal distress, maternal/fetal hyponatremia (with prolonged high-dose IV infusion in hypotonic solutions), cardiac arrhythmias, anaphylaxis, abruptio placentae. ### Key Drug Interactions - **Prostaglandins**: Concomitant use significantly increases risk of uterine hypertonicity and rupture. Avoid simultaneous use; wait at least 6 hours after prostaglandin administration. - **Vasopressors (e.g., ephedrine)**: Enhanced pressor effect, increasing risk of severe hypertension and cerebral hemorrhage. Monitor blood pressure closely. - **Cyclopropane Anesthesia**: Increased risk of cardiac arrhythmias and hypotension. - **Other Oxytocic Agents (e.g., ergot alkaloids)**: Additive uterotonic effects, increasing risk of hypertension and uterine rupture. Avoid co-administration. ## Monitoring & Follow-up - **Before Treatment**: Assess fetal well-being (non-stress test, biophysical profile), confirm fetal presentation, rule out CPD. - **During Treatment**: Continuous fetal heart rate (FHR) and uterine contraction monitoring. Maternal vital signs (BP, HR, RR), fluid balance, and urine output. - **Clinical Signs**: Watch for uterine hyperstimulation (contractions too strong/frequent), FHR abnormalities (e.g., decelerations), signs of fluid overload/hyponatremia (headache, confusion, lethargy). ## Clinical Pearls - 💡 **Titrate Carefully**: Start with the lowest dose and gradually increase; adjust infusion rate based on uterine response and fetal well-being. - 💡 **Infusion Pump Essential**: Always use an infusion pump for IV oxytocin to ensure precise dosage and prevent dangerous bolus administration. - 💡 **Fluid Balance**: Closely monitor for water intoxication/hyponatremia, especially with prolonged high-dose infusions using hypotonic IV solutions. - 💡 **PPH Prevention Timing**: For PPH prevention, administer immediately after anterior shoulder delivery or delivery of the placenta to maximize effectiveness. - 💡 **Emergency Stop**: Discontinue oxytocin immediately if uterine hyperstimulation or signs of fetal distress occur. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.